Evidence-based clinical review Intratumoral Immunotherapy and In-Situ Vaccination: Local Shots, Systemic Responses? What clinicians should know about tumor-directed immune therapy, distant lesion responses, and the limits of current evidence Estimated reading time: 20 minutes Abstract
Tag: precision oncology
ATR and WEE1 Inhibitors After PARP Resistance: Emerging DNA Damage Response Strategies Across Solid Tumors
ATR and WEE1 Inhibitors After PARP Resistance: Emerging DNA Damage Response Strategies Across Solid Tumors Review Abstract Background Resistance to poly(ADP-ribose) polymerase (PARP) inhibition has intensified interest in other components of the DNA damage response and replication-stress network. Early clinical studies have evaluated ataxia telangiectasia
Thrombosis and Cancer Immunotherapy: The Next Frontier of Thromboinflammation
Thrombosis and Cancer Immunotherapy The Next Frontier of Thromboinflammation Review Abstract Cancer immunotherapy has fundamentally transformed the treatment landscape across multiple malignancies, offering durable responses and prolonged survival in patients with previously limited therapeutic options. Immune checkpoint inhibitors, chimeric antigen receptor T cell therapies, bispecific antibodies,
The Microbiome as a Cancer Therapy Lever: Real Clinical Tool or Science Fair?
The Microbiome as a Cancer Therapy Lever: Real Clinical Tool or Science Fair? Abstract The human microbiome has emerged as a potential therapeutic target in oncology, generating considerable interest among researchers and clinicians. This analysis examines current evidence on microbiome-based cancer interventions, evaluating their clinical
